Isan Chen Net Worth

The estimated Net Worth of Isan Chen is at least 4.27 百万$ dollars as of 11 May 2020. Isan Chen owns over 33,334 units of Mirati Therapeutics Inc stock worth over 4,269,545$ and over the last 11 years Isan sold MRTX stock worth over 0$.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Isan Chen MRTX stock SEC Form 4 insiders trading

Isan has made over 7 trades of the Mirati Therapeutics Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently Isan exercised 33,334 units of MRTX stock worth 833,017$ on 11 May 2020.

The largest trade Isan's ever made was exercising 33,334 units of Mirati Therapeutics Inc stock on 11 May 2020 worth over 833,017$. On average, Isan trades about 4,488 units every 126 days since 2013. As of 11 May 2020 Isan still owns at least 72,735 units of Mirati Therapeutics Inc stock.

You can see the complete history of Isan Chen stock trades at the bottom of the page.

What's Isan Chen's mailing address?

Isan's mailing address filed with the SEC is 9393 Towne Centre Dr #200, San Diego, CA 92121, USA.

Insiders trading at Mirati Therapeutics Inc

Over the last 11 years, insiders at Mirati Therapeutics Inc have traded over 179,669,845$ worth of Mirati Therapeutics Inc stock and bought 8,779,906 units worth 186,410,608$ . The most active insiders traders include Healthcare Master Fund Ltd ...、Capital Advisors Llc Aghaza...、Bros. Advisors Lp Baker Bro.... On average, Mirati Therapeutics Inc executives and independent directors trade stock every 22 days with the average trade being worth of 5,885,145$. The most recent stock trade was executed by Benjamin Hickey on 16 January 2024, trading 1,597 units of MRTX stock currently worth 94,255$.

What does Mirati Therapeutics Inc do?

mirati therapeutics develops molecularly targeted, single agent and immuno-oncology combination therapies intended to treat cancer. mirati's approach combines the three most important factors in oncology drug development, 1) researching and developing drug candidates that target genetic and epigenetic drivers of cancer, 2) designing creative and agile clinical development strategies that select for patients whose tumors are dependent on specific driver alterations, and 3) leveraging a highly accomplished oncology precision medicine leadership team. the mirati team uses a blueprint – proven by their prior work – for developing potential breakthrough cancer therapies, with accelerated development paths, in order to improve outcomes for patients. mirati is advancing three drug candidates through clinical development for multiple oncology indications.

Complete history of Isan Chen stock trades at Mirati Therapeutics Inc

Mirati Therapeutics Inc executives and stock owners

Mirati Therapeutics Inc executives and other stock owners filed with the SEC include:

• Charles Baum,
  President, Chief Executive Officer, Director
• James Christensen,
  Executive Vice President, Chief Scientific Officer
• Faheem Hasnain,
  Chairman of the Board
• Julie Cherrington,
  Independent Director
• Dr. Charles M. Baum M.D., Ph.D.,
  Founder, Pres, Head of R&D and Director
• Dr. James G. Christensen Ph.D.,
  Chief Scientific Officer
• Benjamin J. Hickey M.B.A.,
  Chief Commercial Officer
• Bruce Carter,
  Independent Director
• Craig Johnson,
  Independent Director
• Henry Fuchs,
  Independent Director
• Maya Martinez-Davis,
  Independent Director
• Michael Grey,
  Independent Director
• Aaron Davis,
  Independent Director
• Temre Johnson,
  Director, Investor Relations and Corporate Communications
• Joseph Leveque,
  Chief Medical Officer
• Benjamin Hickey,
  Executive Vice President, Chief Commercial Officer
• Daniel Faga,
  Chief Operating Officer, Executive Vice President
• Michael E. Paolucci,
  Chief People Officer
• Laurie D. Stelzer,
  Chief Financial Officer
• Ryan Asay,
  VP & Head of Corp. Affairs
• Dr. Kelly Covello Ph.D.,
  VP & Head of Medical Affairs
• Kristin Gustafson,
  Chief HR Officer
• Reena R. Desai,
  Gen. Counsel & Corp. Sec.
• Vickie S. Reed,
  Sr. VP & Chief Accounting Officer
• David D. Meek,
  CEO & Director
• Rodney W Lappe,
  Director
• Bros. Advisors Lpbaker Feli...,
  
• Capital, Llc Boxer,
  10% owner
• Asset Management Inc. Boxer,
  10% owner
• Mark J Gergen,
  Exec. VP and COO
• Ltd. Braslyn,
  10% owner
• William R Ringo,
  Director
• Christopher C. Lemasters,
  EVP, Chief Business Officer
• Laurie Stelzer,
  Chief Financial Officer
• Capital, Llc Boxer Asset Ma...,
  
• Bros. Advisors Lp Baker Bro...,
  
• Capital Advisors Llc Aghaza...,
  
• Capital, Llc Braslyn Ltd. B...,
  
• Healthcare Master Fund Ltd ...,
  
• Thirteen Inc. Tuesday,
  10% owner
• Capital, Llc Boxer Asset Ma...,
  
• Maria E Martinez,
  
• Neil Reisman,
  10% owner
• Investors, Llc Mva,
  10% owner
• Shehan Bharatha Dissanayake,
  10% owner
• Bros. Advisors Lpbaker Feli...,
  
• Capital, Llc Boxer Asset Ma...,
  
• Capital Management Ltd.Bras...,
  
• Capital Partners Lptang Kev...,
  
• Capital, Llc Boxer Asset Ma...,
  
• Martin Godbout,
  Director
• Jamie A Donadio,
  VP of Finance
• Advisors Llc Orbi Med Capit...,
  
• Felixbaker Julian Baker Bro...,
  
• Vickie S Reed,
  SVP, Chief Accounting Officer
• Isan Chen,
  EVP, Chief Medical Officer
• Shalini Sharp,
  
• Capital, Llc Boxer Asset Ma...,
  
• Ltd.Lewis Joseph Braslyn,
  
• Capital, Llc Boxer Asset Ma...,
  
• David D. Meek,
  Chief Executive Officer
• Jamie Christensen,
  EVP & Chief Scientific Officer
• John B Moriarty,
  Chief Legal Officer
• Carol Giltner Gallagher,
  
• Alan B. Sandler,
  Chief Medical Officer
• Aaron I. Davis,
  
• Capital, Llc Boxer Asset Ma...,